Non-Hodgkin's Lymphoma Market Size, Share and Trends 2026 to 2035

What is the Non-Hodgkin's Lymphoma Market Size in 2026?

The global non-hodgkin's lymphoma market size was estimated at USD 14.10 billion in 2025 and is predicted to increase from USD 15.00 billion in 2026 to approximately USD 26.22 billion by 2035, expanding at a CAGR of 6.40% from 2026 to 2035. The market is driven by growing prevalence and demand for targeted, convenient treatments, driving significant research and development into novel CAR-T and antibody therapies to improve survival rates and patient convenience.

Non-Hodgkin's Lymphoma Market Key Takeaways

• North America dominated the global non-Hodgkin's lymphoma market with a share of 40% in 2025.
• Asia-Pacific is expected to grow at the fastest CAGR of 9.1% during the forecast period.
• By treatment type, the chemotherapy segment contributed the highest nmarket share of 30% in 2025.
• By treatment type, the immunotherapy segment is expected to grow at a strong CAGR of 9.3% between 2026 and 2035.
• By drug class, the monoclonal antibodies segment held a major market share of 40% in 2025.
• By drug class, the CAR T-cell therapy segment is expected to expand at the highest CAGR of 10.5% from 2026 to 2035.
• By route of administration, the intravenous (IV) segment captured the highest non-Hodgkin's lymphoma market share of 50% in 2025.
• By route of administration, the subcutaneous (SC) segment is poised to grow at a healthy CAGR of 8% between 2026 and 2035.
• By end-use industry, the hospitals segment generated the biggest market share of 42% in 2025.
• By end-use industry, the research institutes segment is expanding at the fastest CAGR of 9% between 2026 and 2035.
• By disease subtype, the diffuse large B-cell lymphoma (DLBCL) segment accounted for the largest market share of 40% in 2025.
• By disease subtype, the primary mediastinal B-cell lymphoma (PMBCL) segment is projected to grow at a solid CAGR of 8.5% between 2026 and 2035.

Market Overview

The non-Hodgkin's lymphoma industry involves drugs and treatments for cancers arising in the lymphatic system, driven by rising incidence, advances in immunotherapy, and targeted therapies that are moving away from conventional chemotherapy. The market is undergoing a rapid shift away from conventional chemotherapy toward personalized, targeted solutions such as CAR T-cell therapies. Major industry leaders are accelerating this transition with innovative treatments, offering new, durable options for patients facing high-grade, refractory malignancies.

Non-Hodgkin's Lymphoma Market Trends

• Rapid Adoption of Immunotherapies: CAR-T cell therapies have transformed the treatment of relapsed and refractory NHL, particularly diffuse large B-cell lymphoma and mantle cell lymphoma, offering off-the-shelf efficacy comparable to personalized CAR-T treatments.
• Shift to Earlier Lines of Therapy: Novel targeted agents and immunotherapies are moving from third- or fourth-line to first- or second-line settings, aiming to achieve higher durable responses and potentially curable outcomes earlier in the disease course, thereby transforming the standard of care.
• Expansion of Targeted Therapies and Antibody-Drug Conjugates: The market is seeing strong demand for targeted treatments that minimize systemic toxicity. Key examples include Bruton's tyrosine kinase inhibitors and antibody-drug conjugates such as Polivy and Zynlonta, which deliver chemotherapy directly to cancer cells.
• Focus on Precision Diagnosis and Personalized Medicine: Advancements in genetic profiling and biomarker testing enable highly customized treatment regimens that prioritize patient quality of life, fueling the market shift toward targeted, less toxic therapies.

Key AI Integration in the Non-Hodgkin's Lymphoma Market

Artificial intelligence (AI) is transforming the market by improving diagnosis, personalizing treatment, and accelerating drug discovery through analysis of complex imaging and genetic data. AI models analyze histopathological images and PET/CT scans, with studies demonstrating greater accuracy in classifying subtypes. AI aids in predicting patient response to specific treatments and identifying optimal therapeutic pathways by examining tumor heterogeneity, reducing the time and cost associated with drug development.

Market Scope

Market Dynamics

Driver

The Rising Prevalence of Non-Hodgkin's Lymphoma

This prevalence, especially among the aging population, is significantly increasing the demand for effective treatment options. This growing patient volume is accelerating the shift away from traditional chemotherapy toward high-value targeted immunotherapies, such as CAR-T cell products and bispecific antibodies, which offer enhanced survival rates and more durable remissions.

Restraints

High Treatment Costs and Strict Regulatory Hurdles

The high cost of advanced therapies, such as CAR-T cell treatments and biologics, creates a major barrier to access, limiting widespread market adoption. Furthermore, the stringent regulatory landscape for approving complex genetic and targeted therapies, combined with the risk of adverse effects, significantly slows the commercialization of new drugs.

Opportunity

Expansion of Targeted Therapies in Emerging Markets and Digital Health

Lucrative opportunities are emerging through the expansion of oncology infrastructure and the upgrading of healthcare facilities in emerging economies, facilitating access to advanced NHL treatments. Additionally, the integration of digital health tools, such as AI-driven diagnostic improvements, and increased research and development into combination therapy regimens, is driving future revenue for relapsed and refractory patients.

Segmental Insights

Treatment Type Insights

The Chemotherapy Segment Held a 30% Share of the Non-Hodgkin's Lymphoma Market in 2025

The chemotherapy segment held a dominant position in the market, with a 30% share in 2025. This is due to its foundational role in first-line treatments, high cost-effectiveness, and widespread accessibility. Chemotherapy regimens, such as CHOP, remain the standard first-line treatment for various subtypes of non-Hodgkin lymphoma. The new high-cost therapies, like CAR-T, and chemotherapy more affordable, making it a primary choice in clinical settings. The high prevalence of B-cell lymphomas often requires initial chemotherapy, driving sustained demand.

The immunotherapy segment held 18% of the market share in 2025 and is projected to grow at the fastest CAGR of 9.3% between 2026 and 2035. This growth is fueled by the rapid adoption of CAR T-cell therapies, bispecific antibodies, and novel antibody-drug conjugates that target refractory disease gaps. There is an increased focus on immune checkpoint inhibitors and monoclonal antibodies that target CD20, expanding treatment options. Ongoing research, a robust pipeline of FDA-approved drugs, and earlier integration of these therapies into treatment regimens are further broadening market opportunities.

The targeted therapy segment held the second-largest market share of 22% and is expected to grow at a CAGR of 7.5% during the forecast period. This growth is attributed to the rising demand for precision medicines that offer higher efficacy and fewer side effects compared to traditional chemotherapy. Targeted therapies, including monoclonal antibodies and CAR T-cell therapies, specifically attack cancer cells with high precision, minimizing damage to healthy tissue. This specificity is driving widespread clinical adoption and contributing significantly to revenue growth.

The stem cell transplant segment accounted for 20% of the market share in 2025 and is projected to grow at a CAGR of 6.0% in the coming years. This growth is due to its established role in treating relapsed and refractory disease, allowing for high-dose chemotherapy. Autologous stem cell transplantation is often used as a curative or life-prolonging strategy for aggressive, relapsed, or refractory NHL, which represents a significant portion of the patient population. This makes ASCT a critical, high-value procedure for treating both slow-growing and aggressive lymphomas.

Non-Hodgkin's Lymphoma Market Share, By Treatment Type, 2025-2035 (%)

Drug Class Insights

The Monoclonal Antibodies Segment Dominated with a 40% Share of the Non-Hodgkin's Lymphoma Market in 2025

The monoclonal antibodies segment dominated the market with a 40% share in 2025. This dominance is mainly attributed to their high specificity in targeting tumor cells, significantly improved patient outcomes, and widespread clinical adoption of established agents. The combination of monoclonal antibodies with chemotherapy is the standard of care, ensuring sustained market demand. The availability of biosimilars for blockbuster drugs is also increasing accessibility and affordability, which drives higher adoption rates.

The CAR T-cell therapy segment held 15% of the market share in 2025 and is expected to experience the fastest growth with a CAGR of 10.5% over the studied period. This is driven by its superior efficacy in treating relapsed and refractory cases, particularly with CD19-targeted therapies that focus on high-need, high-response patients. CAR T therapies targeting the pan-B-cell marker CD19 are being used to treat chemotherapy-resistant B-cell NHL. Next-generation, dual-targeting CAR T therapies are enhancing efficacy and durability to overcome antigen escape, improving access to care.

Non-Hodgkin's Lymphoma Market Share, By Drug Class, 2025-2035 (%)

The kinase inhibitors segment held the second-largest market share at 18% in 2025 and is projected to grow at a CAGR of 8.1% during the forecast period. This growth is primarily driven by the shift towards targeted, oral, mechanism-driven therapies. The market is moving away from traditional chemotherapy in favor of targeted agents that offer better efficacy with manageable safety profiles in relapsed and refractory patients. Kinase inhibitors are showing double-digit growth and are outperforming traditional agents as they move into earlier lines of treatment.

The immune checkpoint inhibitors segment accounted for 14% of the market in 2025 and is expected to grow at a CAGR of 9.2% during the forecast period. This growth is due to their high efficacy in treating refractory cases, expanding approval portfolios, and successful combinations with existing therapies. Immune checkpoint inhibitors have shown high response rates in specific relapsed/refractory lymphoma subtypes, particularly classical Hodgkin lymphoma and primary mediastinal B-cell lymphoma. Their increasing use in combination with other novel therapies is boosting adoption rates.

Route of Administration Insights

The Intravenous (IV) Segment Dominated with a 50% Share of the Non-Hodgkin's Lymphoma Market in 2025

The intravenous (IV) segment dominated the market with a 50% share in 2025. This dominance is due to its essential role in administering chemotherapy, monoclonal antibodies, and CAR T therapies, allowing for precise dosing, real-time patient monitoring, and suitability for hospital-based care. IV administration is the primary method for delivering crucial targeted therapies and monoclonal antibodies that require controlled infusion speeds. It enables immediate, bioavailable drug delivery for managing moderate-to-severe lymphoma cases with real-time patient monitoring.

The subcutaneous (SC) segment held 25% of the market share in 2025 and is projected to experience the fastest growth with a CAGR of 8.0% in the coming years. This expansion is primarily driven by its potential to enhance patient convenience, improve healthcare efficiencies, and reduce treatment costs. The shift from lengthy hospital stays to quicker clinic visits, and eventually home settings, increases patient convenience and alleviates the burden of care. SC formulations enable fixed-dose regimens that do not require body weight calculations, thus enhancing safety and convenience.

The oral segment held 25% of the market share in 2025 and is expected to grow at a robust CAGR of 7.5%. This growth is fueled by the rapid adoption of targeted therapies, the convenience they offer for long-term treatment, and the increasing preference for outpatient care. Oral treatments are favored for their ease of use, particularly among elderly patients or for long-term maintenance therapy where constant intravenous infusion is impractical, making them more appealing to both patients and clinicians.

Non-Hodgkin's Lymphoma Market Share, By Route of Administration, 2025-2035 (%)

End-use Industry Insights

The Hospitals Segment Dominated with a 42% Share of the Non-Hodgkin's Lymphoma Market in 2025

The hospitals segment dominated the market with a 42% share in 2025. This dominance is mainly attributed to the central role of hospitals in administering complex, high-cost, and specialized treatments, such as CAR-T cell therapies and intravenous immunotherapies, which necessitate inpatient care. Hospitals serve as the primary setting for sophisticated treatments and monoclonal antibody therapies. These facilities are well-equipped to manage the entire treatment cycle, including diagnosis, inpatient chemotherapy administration, specialized oncology services, and follow-up care.

The research institutes segment held 10% of the market share in 2025 and is projected to experience the fastest growth with a CAGR of 9.0% during the projected period. This is primarily due to increasing investments in CAR-T cell therapies, molecular profiling, and early-stage clinical trials. Their growth is driven by the development of precision medicines and personalized diagnostics aimed at improving treatment efficacy. Research centers are heavily focused on creating novel targeted agents and CAR-T therapies, thus accelerating the pace of innovation within these institutions.

Non-Hodgkin's Lymphoma Market Share, By End-use Industry, 2025-2035 (%)

The oncology clinics segment held the second-largest market share at 28% in 2025 and is expected to grow at a considerable CAGR of 7.5%. This growth is largely due to the rapid adoption of outpatient specialized care and the increasing capacity of these clinics to administer advanced targeted therapies and biologics. Many clinics are now equipped to provide complex treatments such as immunotherapies, allowing them to compete with hospital-based care and boosting the utilization of specialty oncology centers.

The homecare segment captured 10% of the market share in 2025 and is expected to grow at a CAGR of 6% during the forecast period. This growth is driven by the rising need for manageable treatment options and the increasing availability of at-home targeted therapies. Escalating healthcare costs are prompting payers and patients to seek home-based care as a cost-effective alternative to traditional hospital-intensive regimens, which reduces expenses associated with hospital stays and lengthy intravenous sessions in clinics.

Disease Subtype Insights

The Diffuse Large B-cell Lymphoma (DLBCL) Segment Held the Largest Market Share of 40% in 2025

The diffuse large B-cell lymphoma (DLBCL) segment dominated the non-Hodgkin's lymphoma market with a share of 40% in 2025. This dominance is largely due to its high incidence rate, aggressive nature requiring immediate treatment, and the rapid adoption of novel targeted therapies. As the most common subtype of non-Hodgkin lymphoma, DLBCL's fast-growing nature demands rapid, intensive treatment, leading to high therapeutic consumption. This subtype comprises distinct molecular variations, including germinal center B-cell-like characteristics, making targeted drugs effective.

The primary mediastinal B-cell lymphoma (PMBCL) segment held 5% of the market share in 2025 and is expected to achieve the fastest growth with a CAGR of 8.5% in the coming years. This growth can be attributed to the high efficacy and increased adoption of novel antibody-drug conjugates, such as Pola-R-CHP, for refractory cases. Given its aggressive nature, PMBCL, commonly found in younger female populations, is increasingly treated with personalized protocols that minimize the need for radiotherapy. Real-world analyses indicate that Pola-R-CHP shows promise in overcoming resistance to initial therapies for advanced care.

Non-Hodgkin's Lymphoma Market Share, By Disease Subtype, 2025-2035 (%)

The follicular lymphoma (FL) segment held the second-largest market share at 30% in 2025 and is expected to grow at a CAGR of 5.9% during the forecast period. This growth is primarily attributed to its high prevalence as an indolent B-cell cancer and the chronic nature of the disease, which necessitates multiple lines of therapy. Additionally, the robust pipeline of targeted therapies and the high costs of treatment contribute to this trend. FL is the most common type of indolent lymphoma and is often considered incurable, which requires prolonged treatment over many years.

The mantle cell lymphoma (MCL) segment accounted for 10% of the market share in 2025 and is expected to grow at a CAGR of 7.3% over the studied period. This segment's growth can be attributed to its aggressive nature, the rising incidence of aging populations, and the high cost of specialized targeted therapies. Due to the aggressive characteristics of MCL and frequent relapses, patients often require multiple lines of treatment, including chemotherapy, targeted agents, and stem cell transplants, which increases the cumulative cost per patient and drives the adoption of these premium therapies.

Regional Insights

North America Non-Hodgkin's Lymphoma Market Size and Growth 2026 to 2035

The North America non-hodgkin's lymphoma market size was exhibited at USD 5.64 billion in 2025 and is projected to be worth around USD 10.62 billion by 2035, growing at a CAGR of 6.53% from 2026 to 2035.

North America Dominated the Global Non-Hodgkin's Lymphoma Market in 2025

North America held a major market share of 40% in 2025. This dominance is mainly due to the high incidence of the disease, advanced healthcare infrastructure, and the rapid adoption of high-cost targeted therapies and immunotherapies. The increasing geriatric population, with a high incidence rate of B-cell lymphomas, consistent demand for treatment. Access to advanced oncology centers and specialized diagnostic techniques supports the adoption of premium therapies. Major pharmaceutical companies like Gilead Sciences, Bristol Myers Squibb, and AbbVie lead in CAR-T cell and immunotherapy research.

U.S. Non-Hodgkin's Lymphoma Market Size and Growth 2026 to 2035

The U.S. non-hodgkin's lymphoma market size was exhibited at USD 4.23 billion in 2025 and is projected to reach around USD 8.02 billion by 2035, with a CAGR of 6.61% from 2026 to 2035.

U.S. Market Trends

The U.S. plays a crucial role in the market by promoting the rapid adoption of breakthrough CAR-T cell therapies and bispecific antibodies. Supported by significant healthcare investments and advanced clinical infrastructure, the U.S. is aggressively advancing initiatives, including landmark FDA approvals for therapies, solidifying its position as a leader in achieving durable, targeted remissions for non-Hodgkin lymphoma.

Asia-Pacific is Undergoing the Fastest Growth in the Non-Hodgkin's Lymphoma Market.

Asia-Pacific held 20% of the market share in 2025 and is expected to experience the fastest growth with a CAGR of 9.1% during the predicted timeframe. This growth is driven by an increasing disease burden, rapid improvements in healthcare infrastructure, and the adoption of advanced targeted therapies and immunotherapies. The region is witnessing a surge in NHL cases, particularly influenced by an aging population and changing lifestyle factors, especially in countries like China and India. Increased healthcare spending, improved diagnostic techniques, and better access to advanced treatment options, such as immunotherapy and CAR-T cell therapy, are propelling market growth.

India Market Trends

India is quickly evolving from a generic manufacturer into a global innovation leader, transforming care for its large underserved population through affordable, locally produced CAR-T cell therapies. The rise of breakthrough, domestically manufactured treatments is paving the way for accessible, high-tech immunotherapy. Strategic partnerships utilizing AI technologies under initiatives like the National Cancer Grid and global collaborations are further establishing its role as a key player in this market.

Europe Experiencing Notable Growth in the Non-Hodgkin's Lymphoma Market

Europe held 28% of the market share in 2025 and is expected to experience notable growth with a CAGR of 6.2% during the forecast period. This growth is primarily driven by increasing incidence rates due to an aging population, high adoption of advanced, costly therapies, and increased healthcare investment in diagnostics and treatment. Europe is facing a steady rise in NHL cases among individuals over 60, with Germany and France reporting significant increases. The market is shifting from conventional chemotherapy toward targeted methods, including CAR-T cell therapies and bispecific antibodies, offering higher efficacy for refractory cases.

Germany Market Trends

Germany is accelerating the future of oncology by capitalizing on its aging population, rapidly approving reimbursement for high-cost biologics, and streamlining CAR-T cell therapy approvals. Through advanced treatment integration, including bispecific T-cell engagers, and innovative cross-border research initiatives, Germany acts as a key catalyst in Europe for bringing cutting-edge targeted therapies from research labs to clinical practice.

Top Companies in the Non-Hodgkin's Lymphoma Market

• Roche
• Bristol Myers Squibb
• Novartis
• Gilead Sciences
• Eli Lilly and Co.
• Merck & Co.
• Amgen
• AbbVie
• Pfizer
• Bayer
• AstraZeneca
• Sanofi
• Johnson & Johnson
• Seagen
• Baxter International

Segments Covered in the Report

By Treatment Type

• Chemotherapy
• Targeted Therapy
• Immunotherapy
• Radiation Therapy
• Stem Cell Transplant

By Drug Class

• Monoclonal Antibodies
• Kinase Inhibitors
• Immune Checkpoint Inhibitors
• CAR-T Cell Therapy
• Antineoplastic Agents

By Route of Administration

• Intravenous (IV)
• Subcutaneous (SC)
• Oral

By End-Use

• Hospitals
• Oncology Clinics
• Research Institutes
• Homecare

By Disease Subtype

• Diffuse Large B-cell Lymphoma (DLBCL)
• Follicular Lymphoma (FL)
• Mantle Cell Lymphoma (MCL)
• Primary Mediastinal B-cell Lymphoma (PMBCL)
• Others

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa